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Summary 
 
The Casitas B-lineage lymphoma (Cbl) family of ubiquitin ligases has been studied for years 
regarding their important role in downregulation of ligand bound epidermal growth factor 
receptor (EGFR). The two isoforms c-Cbl and Cbl-b share the same structural features and 
are thought to be equally important for EGFR downregulation. Few comparative studies 
between c-Cbl and Cbl-b have been published with respect to EGFR regulation. Even though 
both Cbl proteins appear to display the same functional activity in EGFR regulation, some 
studies reveal that there might be some differences between these two isoforms. In this study, 
we have used biochemical studies and live imaging to further investigate and compare the 
recruitment and intracellular trafficking of c-Cbl and Cbl-b upon EGF stimulation.  
 
Summarized, Cbl-b is recruited more efficiently to EGFR than c-Cbl upon receptor 
activation. However, this difference in recruitment does not seem to affect their trafficking, 
as both isoforms follow the same trafficking pattern to early endosomes.  
 
The finding that Cbl-b is recruited to the EGFR more efficiently than c-Cbl is recruited to the 
EGFR, implies that they could have distinct activities at early time points. Due to their 
important roles in downregulation of growth factor signaling, further investigations regarding 
their individual functions are of great importance.  
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1 Introduction 
 
1.1 Growth factor receptors 
Cells constitute the basic building blocks in every living organism and are dependent on 
numerous different growth factors in order to maintain normal growth, development and for 
maintaining homeostasis. In multicellular organisms, these growth factors are especially 
important signals in cell-to-cell communications during tissue development, cell migration, 
cell survival and apoptosis in embryogenesis. 
 
Growth factors bind to the extracellular part of specific receptors located in the plasma 
membrane, which lead to conformational changes and activation of the intracellular part of 
the receptor. The receptor activation induces specific intracellular signaling pathways 
dependent on the type of growth factor, which in turn lead a cellular response. The final 
outcome of the cellular response is dependent on the duration and intensity of the signaling 
combined with the activity of various signaling proteins involved in these pathways. The 
activities of the intracellular signaling pathways are carefully controlled by other proteins in 
order to prevent excessive growth response. Another important mechanism involved in signal 
attenuation is the removal of the receptor-ligand complex from the cell surface.  
  
Most of these growth factor receptors have a similar molecular structure, with the well 
characterized receptor family receptor tyrosine kinases (RTKs) as a typical member. The 
RTKs are transmembrane proteins containing an extracellular ligand binding part and an 
intracellular tyrosine kinase domain responsible for activation of signaling pathways. These 
receptors are  therefore capable of transforming the extracellular binding of a specific type of 
growth factor  into activation of several specific intracellular signaling pathways. These 
signaling pathways are carefully regulated, ensuring a controlled cellular response. 
Dysregulation of growth signals by mutations in RTKs or disturbance in intracellular 
signaling pathways is implicated in various diseases such as cancer, diabetes and 
inflammation (Wieduwilt and Moasser, 2008).  
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The RTKs have been extensively studied for years and have revealed important insights into 
their structure and regulation. The increased understanding of their nature has been important 
for the development and improvement of drugs. 
 
1.2 The Epidermal Growth Factor receptor  
The epidermal growth factor receptor (EGFR) is one of four members in the epidermal 
growth factor family of receptor tyrosine kinases (ErbBs), all of which share homologous 
sequences. The ErbB family consists of the EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 
(HER3) and ErbB4 (HER4), which are essential in regulating cellular differentiation, 
proliferation, migration and survival (Wieduwilt and Moasser, 2008). They are one of at least 
58 discovered human members of transmembrane RTKs, which all share a conserved 
structure and function and are necessary for regulating normal cellular processes (Lemmon 
and Schlessinger, 2010).  
 
EGFR is expressed in cells with epithelial, mesenchymal and neuronal origin and is 
important for regulating cell development, proliferation, migration and for maintaining 
homeostastis (Yano et al., 2003). It is distributed on the basolateral surface on epithelial cells 
where it is are able to bind secreted ligands exclusively on this side. In this way, the receptor 
can interact with growth factors promoting cell proliferation and migration, both processes 
required for wound healing. Also, the tight junctions between the epithelial cells creates a 
barrier towards growth factors that are secreted onto the apical side. If this barrier is broken,  
for instance by a wound, growth factors gain access to receptors on the basolateral side. 
When the barrier is restored due to epithelial growth, the wound is healed and growth factors 
can no longer access the receptors (Vermeer et al., 2003). This asymmetrical distribution 
contributes to the polarization in the epithelial cell, which is important for the directional 
transport of molecules. Loss of polarity is often implicated in epithelial cancers, giving EGFR 
access to apically located growth factors. This in turn may result in sustained or prolonged 
growth signaling and thus uncontrolled cell migration or cell proliferation (Casaletto and 
McClatchey, 2012).  
 
Normally, the cell density and amount of cell-to-cell contact regulates the activity of EGFR 
and in this way also controls the epithelial tissue growth (Kim et al., 2009). Knockout of 
EGFR has been reported to result in embryonic lethality in mice (Threadgill et al., 1995) and 
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deficient development of epithelial tissues in many vital organs (Miettinen et al., 1995; 
Sibilia and Wagner, 1995). Mutations or dysregulation of EGFR is also involved in the 
development of colorectal cancer (Krasinskas, 2011), non-small-cell lung cancer (Gorgoulis 
et al., 1992), head and neck cancer (Irish and Bernstein, 1993) and glioblastomas (Wong et 
al., 1992).  
 
EGFR has been studied for decades and has become the receptor model for studying 
mechanisms underlying receptor tyrosine kinase signaling and signaling attenuation. Correct  
attenuation of receptor signaling is crucial for controlled cell growth. One important 
regulatory mechanisms is to rapidly remove the receptor from the plasma membrane by 
endocytosis, a mechanism involving many adaptor proteins and enzymes (Casaletto and 
McClatchey, 2012). Among these is the ubiquitin ligase Casitas B-lineage lymphoma (Cbl) 
family that attaches ubiquitin onto lysine residues in the cytoplasmic tail of the receptor, a 
modification that further recruits other adaptor proteins and targets the receptor for 
internalization and transport to lysosomes for degradation. Also, recent studies of EGFR  
structure and behavior have gained additional knowledge that facilitates the development of 
new cancer drugs (Endres et al., 2011).  
 
1.2.1 EGFR structure 
The ErbB familyof receptors are all transmembrane proteins, consisting of an extracellular 
glycosylated N-terminal domain containing ligand binding sites and cysteine-rich domains 
for dimerization, a transmembrane section, a small juxtamembrane segment, and an 
intracellular C-terminal domain containing a number of tyrosine phosphorylation (pY) sites 
and a tyrosine kinase domain (Bazley and Gullick, 2005) (figure 1-1).  
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Figure 1-1. ErbB receptor structure. The ErbB receptor family are transmembrane proteins with an 
extracellular N-terminal domain, a transmembrane domain, a small juxtamembrane domain (JM), and a C-
terminal cytoplasmic part. The N-terminal part contains ligand binding sites (L1/L2) and cysteine residues (S1 
and S2), S1 are invloved in EGFR dimerization. The C-terminal domains consists of a protein kinase domain 
(SH1) and tyrosine residues that become phosphorylated upon receptor activation (orange part). Modified from 
(Bazley and Gullick, 2005) 
 
 
EGFR is the only member of the ErbB famliy which is capable of rapid ligand-induced 
endocytosis (Baulida et al., 1996). Seven different ligands can bind to the EGFR (Hynes and 
MacDonald, 2009) and they all induce internalization from the plasma membrane (PM). 
However, after internalization from the PM each of them triggers different mechanisms of 
intracellular sorting of the receptor, either to the recycling or the degradative pathway. 
Ligands which dissociate from the receptor in early endosomes induce receptor recycling 
(transforming growth factor- (TGF-), epiregulin (EPI), amphiregulin (AR)), whereas 
others that remain bound lead to further receptor sorting to lysosomes for degradation (EGF, 
heparin-binding EGF (HB-EGF), betacellulin (BTC)) (Roepstorff et al., 2009). Of these 
ligands, EGF has been the most used ligand when studying trafficking and downregulation of 
EGFR, as it is the founding member of the EGF family of proteins (Carpenter and Cohen, 
1979). 
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1.2.2 EGFR activation and signaling 
Upon binding of EGF, the EGFR forms an asymmetric kinase dimer leading to activation of 
the tyrosine kinase domain. This event induces transphosphorylation of tyrosines in the 
cytoplasmic tail, by which a specific tyrosine kinase domain in one of the receptors (activator 
kinase) bind to the head of the other tyrosine kinase domain (receiver kinase). This in turn 
leads to a conformational change where the receiver kinase phosphorylates tyrosines both on 
its own tail and the dimerization partner (figure 1-2)  (Endres et al., 2011).  
 
     
        
Figure 1-2. EGF receptor activation. In the inactivate state, EGFRs are mainly distributed as monomers across 
the cell membrane. Upon ligand binding, the receptors dimerize in an asymmetric manner leading to activation 
of the intrinsic tyrosine kinase activity and autophosphorylation of distinct tyrosine residues in the cytoplasmic 
tail. 
 
 
This autophosphorylation event creates binding sites for proteins containing phosphoryrosine 
binding domains, such as the Src-Homology 2 (SH2)-domain. Two of the major proteins 
recruited to the phosphotyrosine sites are the adaptor protein growth factor receptor-bound 
protein 2 (Grb2) and Shc. Grb2 is fast recruited to pY1068 and pY1086 in the cytoplasmic 
tail of the EGFR upon its activation, at which it binds through its SH2 domain. Grb2 is also 
bound to and recruits to the EGFR Son-of-Sevenless (SOS), a Ras a guanine-exchange factor 
that activates Ras GTPase located at the PM. Grb2 may also bind to the receptor indirectly by 
associating with Shc through its SH3 domain, at which Shc binds directly to phosphotyrosine 
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residues through its SH2 domain. Activation of Ras leads to activation of the well 
characterized mitogen-activating protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) signaling pathway which ultimately regulates DNA transcription. Additionally 
other signaling pathways are induced upon EGFR activation, such as PI3P/Akt signaling that 
regulates cell proliferation and survival. At the same time, Grb2, which is involved in signal 
transduction, also induces receptor internalization by recruiting proteins responsible for 
receptor endocytosis (Schlessinger et al., 1983; Sorkin and von Zastrow, 2009; Yarden and 
Schlessinger, 1987a; Yarden and Schlessinger, 1987b). The type of ligand binding to the 
EGFR determines the sites of autophosphorylation, which in turn regulates the activation of 
specific signaling proteins and ultimately regulation of gene expression and thus cellular 
response (Olayioye et al., 1998). Figure 1-3 illustrates the major signaling pathways initiated 
by the ligand bound activated receptor. 
 
 
                       
Figure 1-3. EGFR signaling. Upon  receptor activation by ligand binding, the receptor initiates downstream 
signaling by recruiting several effector proteins involved in different signaling pathways ultimately leading to 
specific cellular responses. 
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Activated, ligand bound EGFR continues to induce intracellular signaling on endosomes as 
long as it exists in a phosphorylated state, sustaining the interaction with effector proteins 
such as Grb2, Shc and SOS. Thus, peristent EGF receptor signaling both from the PM and on 
endosomes could ultimately lead to uncontrolled cell growth and proliferation. Attenuation of 
signaling is controlled by receptor modification by ubiquitin, receptor dephosphorylation and 
ligand dissociation at the lower pH found in later endosomes (Lai et al., 1989; Sorkin and 
Carpenter, 1991).  
 
1.3 Endosomal trafficking  
Endocytosis is a general term for the cellular uptake and intracellular sorting of extracellular 
material, such as nutrients, cell surface receptors, plasma membrane lipids and other soluble 
particles. Several uptake mechanisms have been identified, depending on the type of cargo  
(Scita and Di Fiore, 2010). A well-studied endocytic route is clathrin-mediated endocytosis, 
where extracellular cargo is selected by adaptor proteins into specialized areas at the PM 
called clathrin coated pits followed by intracellular transport in clathrin coated vesicles. 
Clathrin-mediated endocytosis is described as the main endocytic route, especially for the 
internalization of plasma membrane receptors (Doherty and McMahon, 2009). Clathrin and 
adaptor protein 2 (AP2) are the main components in the clathrin coated pits. The uptake of 
extracellular cargo through this route is initiated by the cooperation of adaptor proteins which 
recognize and bind the cargo and lastly recruit clathrin triskelia to coat the forming clathrin 
coated pit at the PM. AP2 or other cargo-specific adaptor proteins, are responsible for the 
recognition and binding of cargo, and further recruit clathrin triskelia from the cytosol to 
areas containing adaptor proteins. The clathrin polymerization leads to stabilization of the 
membrane curvature, assisted by other adaptor proteins, like the epsins. The membrane 
scission is mediated by the enzymatic activity of dynamin. After budding from the plasma 
membrane, other adaptor proteins such as auxillin or G-associated kinase, recognizes clathrin 
inducing dissociation and recycling of clathrin, which lastly produces a cargo-containing 
endosome (McMahon and Boucrot, 2011).   
 
Once internalized, extracellular cargo enters early endosomes and becomes further sorted to 
distinct destinations, such as lysosomal degradation, recycling to the plasma membrane or 
retrotransport to Golgi, all depending on the type of trafficking route they encounter. The 
sorting processes during endosomal pathways are highly dynamic and complex, where 
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effector proteins on the early endosome determine the fate of the cargo (Sigismund et al., 
2012). 
1.3.1 Endosomal trafficking of EGFR 
Clathrin-mediated endocytosis is considered to be the most common endocytic route of the 
EGFR, although other endocytic pathways have been suggested. The type of uptake of the 
receptor depends on the ligand concentration: lower ligand concentrations favor clathrin 
mediated endocytosis and higher concentrations favor clathrin independent endocytosis (Goh 
et al., 2010; Sigismund et al., 2005).  
 
Upon activation by ligand binding, the EGFR becomes ubiquitinated by the E3 ligase Cbl 
followed by recruitment of ubiquitin (ub) binding proteins, like Eps15 and epsin, which 
interacts with other components in clathrin coated pits. This event leads to translocation of 
the EGFR into clathrin coated pits followed by invagination and pinching off from the 
clahtrin coated invagination (McMahon and Boucrot, 2011). Ligand bound, active and 
ubiquitinated receptor is sorted towards lysosomal degradation while receptors with no ligand 
becomes deubiquitinated and are sorted for recycling back to the plasma membrane. 
Internalized ligand bound receptor enters early endosomes, where ubiquitinated receptors are 
sorted into intraluminal vesicles (ILVs), destined for lysosomal degradation. This sorting 
process is controlled by the endosomal sorting complex required for sorting (ESCRT), a 
group of proteins located on early endosomes that recognizes ubiquitinated cargo and 
prevents the recycling by mediating invagination of cargo into intraluminal vesicles and in 
turn creating multivesicular bodies (MVBs). The ESCRT-complexes consist of four protein 
complexes ESCRT-0,-I,-II and -III that cooperate during the sorting of ubiquitinated cargo 
(Raiborg and Stenmark, 2009). The first complex, ESCRT-0, consists of a Hrs and STAM 
complex, which specifically binds ubiquitinated proteins and clathrin (Bache et al., 2003; 
Raiborg et al., 2002). Further, ESCRT-I (Katzmann et al., 2001) and ESCRT-II (Babst et al., 
2002b) mediates the invagination of the membrane containing the cargo, while ESCRT-III 
finally pinches them off creating intraluminal vesicles (Babst et al., 2002a). During the 
sorting, ub is removed from cargo by deubiquitinating enzymes (DUBs), which ensure 
recycling of ub back to the cytoplasmic pool for new rounds of ubiquitination (Wright et al., 
2011). Once sorted into ILVs, the receptor is transported towards lysosomes for degradation 
(Futter et al., 1996). Figure 1-4 summarizes the endocytic trafficking of the EGFR. 
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Figure 1-4. Model of  EGFR endocytosis. Receptors activated by ligand binding are ubiquitinated by E3 
ligases (Cbl) in order to be internalized, followed by sorting to lysosomes for degradation. High concentrations 
of ligand mediate clathrin-independent endocytosis while low ligand concentrations mediates clathrin- mediated 
endocytisis. During sorting into inner vesicles of early endosomes and MVB by the ESCRT complex, the 
ubiquitin molecules attached to the ligand bound  receptor are removed by deubiquitinating enzymes in order to 
be recycled back to the cytoplasmic pool. Internalized receptors that are inactivated due to ligand dissociation 
are recycled back to the membrane as the cytoplasmic tail of the receptor is not ubiquitinated and thus not 
marked for lysosomal sorting . Figure from (Haglund and Dikic, 2012) 
 
 
1.4 Ubiquitination 
Ubiquitin is a 76 amino acid residue protein that can be covalently attached to other cellular 
proteins. Conjugation of ubiquitin (ubiqutination) is a reversible post-translational 
modification that may regulate the protein’s localization, interaction partners, half-life and 
structure. In this manner, ubiquitin regulates several important cellular processes such as 
protein degradation, endocytic trafficking, DNA repair and transcription, autophagy, 
inflammation and immune responses (Woelk et al., 2007). 
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These ubiquitin modifications occur by covalent bonding through an isopeptide bond 
between the C-terminal domain on ubiquitin and the ε-aminogroup on the lysine (Lys) 
residue of the target protein (Goldknopf et al., 1977; Hershko et al., 1980), a step carried out 
by ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2) and ubiquitin 
ligases (E3) (Hershko et al., 1983). The process starts with the ATP-consuming activation of 
ubiquitin by the E1 enzymes, linking ubiquitin to E1 by a thioester bond, followed by transfer 
of the ubiquitin to the E2 enzymes by making a thioester bond. The E2 enzymes are then 
recruited to the E3 ligases, which recognize the target protein and finally conjugate the 
ubiquitin to lysines in the target substrate (figure 1-5 A). In this manner, the E3 ligase 
determines the type of ubiquitin modification and thus the fate of the target substrate 
(Husnjak and Dikic, 2012). There are two major families of E3 ligases, described below in 
section 1.4.1.  
 
Ubiquitin can itself become ubiquitinated. Seven Lys residues in ubiquitin make it possible to 
create different kinds of modifications on the target substrate, and in this way determine the 
fate of the target substrate (summarized in figure 1-5 B). Essentially, ubiquitin can be 
attached to the substrate as one or more single moieties (mono- and multiple mono-
ubiquitination) or in ubiquitin chains (polyubiquitination), where several ubiquitin moieties 
are covalently attached through isopeptide bonds (Husnjak and Dikic, 2012). Of these 
possible modifications, multiple monoubiquitination and a combination of ubiquitin chains 
have been under focus regarding their role in regulation of endocytic trafficking and 
downregulation of receptor tyrosine kinases, with EGFR as a model (Haglund et al., 2003; 
Huang et al., 2006; Mosesson et al., 2003). 
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Figure 1-5. Ubiquitin modification. A: The sequential action between ubiquitin activating enzymes (E1), 
ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3) regulate the ubiquitination by breaking the 
isopeptide bond between target and ubiquitin. B: Various ubiquitin modifications determines the fate of the 
target substrate. Figure from (Husnjak and Dikic, 2012). 
 
1.4.1 Ubiquitin ligases 
As mentioned above, E3 ligases determines the fate of the substrate by identifying it as a 
target substrate for ubiquitination. There are two main groups of E3 ligases, RING (really-
intereresting-new-gene) finger E3 ligases and HECT (homologous to E6-AP carboxy 
terminus) domain E3 ligases. The zinc-binding RING finger domain ligases mediates 
ubiquitination by binding the E2 and mediating the transfer of ubiquitin from E2 directly to 
the substrate linking ubiquitin to Lys residues in the substrate by a isopeptide bond (Freemont 
et al., 1991; Xie and Varshavsky, 1999), whereas for the HECT domain ligases ubiqutin is 
conjugated to the E3 ligase by a thioester bond before conjugating ubiquitin to Lys in the 
B 
A 
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substrate by a isopeptide bond (Huibregtse et al., 1995). DUBs regulate the level of protein 
ubiquitination by removing ubiquitin by cleaving of the ubiquitin-lysine isopeptide bond 
(Komander et al., 2009). 
 
The RING finger E3 ligase Cbl is one of the most studied E3 ligases due to its important role 
as a negative regulator of various plasma membrane receptors, especially in the case of the 
downstream signaling of receptor tyrosine kinases like EGFR (Thien and Langdon, 2005). 
 
1.5 The Cbl family 
The Cbl proteins are evolutionary conserved RING finger E3 ligases that are ubiquitously 
expressed, both in mammals and non-mammals (chicken (Gallus gallus), zebra fish (Danio 
rerio), frog (Zenopu tropicalis), fly (Drosphila melanogaster), worm (Caenorhabditis 
elegans) and amoeba (Dictyostelium discoideum)) (Mohapatra et al., 2013). Dysfunction or 
lack of Cbl may lead to various severe disorders, such as immune diseases and cancer (Ryan 
et al., 2006). 
 
c-Cbl (Cbl) was the first member to be characterized as a cellular homologue of v-Cbl, a 
truncated oncogenic of c-Cbl expressed in Cas-Br-M virus that induces pre-B cell 
lymphomas in mice. Due the oncogenic potential in the truncated form, c-Cbl was thus 
characterized as a proto-oncoprotein (Blake et al., 1991; Langdon et al., 1989a). Two other 
mammalian members were later discovered: Cbl-b (Keane et al., 1995) and Cbl-3 (Cbl-c, 
Cbl-SL) (Keane et al., 1999).  
 
1.5.1 Cbl structure 
The Cbl family members all have a conserved N-termini containing a tyrosine kinase binding 
domain (TKB) and a RING finger domain. The C-terminal domain is more divergent, which 
in its full length form contains proline rich regions, tyrosine phosphorylation sites and a 
ubiquitin associated domain (UBA) overlapping with a leucine zipper motif (LZ) (figure 1-6 
A) (Huang, 2010). The TKB domain contains a four-helical bundle (4H), a calcium-binding 
EF domain and a SH2 domain. TKB recognizes phosphotyrosine residues on the substrate 
and translocates Cbl to the target protein (Meng et al., 1999). The RING finger domain serves 
as a binding site for the E2 ligase and is thus important for the E3 ligase activity (Joazeiro et 
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al., 1999). The proline rich domain and the pY residues in the C-terminal domain have 
binding sites for proteins containing SH3-motifs and SH2-motifs, making them important 
sites for interaction with adaptor- and signaling proteins. Cbl-3 has a much shorter proline-
rich domain and thus interact with fewer proteins than c-Cbl and Cbl-b (Goh et al., 2010). 
 
Once bound to the substrate, c-Cbl and Cbl-b are activated by phosphorylation of the tyrosine 
residues Y371 and Y363 in the linker region, respectively, by tyrosine kinases (Kassenbrock 
and Anderson, 2004). Both of these Cbl-isoforms have an UBA domain, but the tendency of  
ubiquitin binding through the UBA domain is different in c-Cbl and Cbl-b, as Cbl-b has 
higher ubiquitin-binding affinity than c-Cbl (Davies et al., 2004). Lastly, the LZ motifs are 
involved in the homodimerization of Cbl (Alber, 1992; Busch and Sassone-Corsi, 1990) 
(figure 1-6 B). 
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Figure 1-6. Cbl protein structure. A: The evolutionary conserved N-terminal region of the Cbl proteins 
contains a tyrosine kinase binding domain (TKB), a RING finger domain (RF) and a proline rich domain. The 
C-termimal region is more divergent and contains phosphotyrosine residues between the proline rich region and 
a ubiquitin associated domain (UBA) fused to a leuzine zipper domain (LZ). Modified from (Huang, 2010). B: 
TKB recognizes and binds to phosphorylated tyrosine residues on target protein. Meanwhile, ubiquitin 
activating enzymes (E1) load ubiquitin and activate ubiquitin conjugating enzymes (E2). The activated E2 binds 
to the RING finger domain (RF) in Cbl, which further transfers ubiquitin to lysines in the target protein. Figure 
from Lene E. Johannessen. 
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1.5.2 The function and regulation of Cbl 
The Cbl proteins have been extensively studied for their role in the internalization, trafficking 
and downregulation of the EGFR (Meisner and Czech, 1995; Yoon et al., 1995) and also in 
regulation of other growth factor- and immune receptors. In addition, they play an important 
role in regulating actin polymerization, focal adhesions and integrin through adaptor proteins 
that are directly involved in these processes (Huang, 2010). Since they are essential in the cell 
function and development, the regulation of Cbl proteins is crucial. A mechanism to control 
their activity is through ubiquitination of the Cbl proteins by HECT E3 enzymes, which 
target Cbl for proteasomal degradation (Ryan et al., 2006). It has also been proposed that 
lysosomes may mediate degradation of Cbl (Ettenberg et al., 2001).  
 
1.5.3 The physiological function of c-Cbl and Cbl-b 
c-Cbl is highly expressed in the thymus, serving as an important regulator for hematopoietic 
stem cells, and testis (Langdon et al., 1989b). It is also expressed in other organs as the 
spleen, lung, heart, brain as well as in T- and B cells (Huang, 2010; Rathinam et al., 2008).  
Like c-Cbl, Cbl-b is also expressed in hematopoietic cells, thymus, testis, heart, lung and 
brain. In addition, Cbl-b is expressed in the ovary, placenta, prostate, kidney, liver, skeletal 
muscles and especially in the spleen (Huang, 2010; Keane et al., 1995).  
 
Mutations in c-Cbl and Cbl-b have been implicated in immune disorders, such as leukemia, 
due to their important role in the regulation of immune receptors in hematopoietic stem cells 
(Naramura et al., 2010; Rathinam et al., 2010). Other studies have shown that knockout of 
both c-Cbl and Cbl-b is associated with early embryonic lethality, suggesting an important 
role in embryonic development (Naramura et al., 2002).  
 
The patterns of expression levels for c-Cbl and Cbl-b in different tissues also reflect the 
important roles for each of them. As c-Cbl is preferentially expressed in the testis and 
thymus, deletion of c-Cbl in germ-cells in mice has been shown to be involved in reduced 
male fertility (El Chami et al., 2005), increased cellular populations in lymphoid organs 
(Murphy et al., 1998; Rathinam et al., 2008), and alteration of positive selection of T-cells in 
the thymus (Naramura et al., 1998). On the other hand, Cbl-b deficient germ-cells in mice do 
not seem to promote abnormal developments, but rather lead to autoimmune diseases by 
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inducing hyperactive T-cell responses (Bachmaier et al., 2000; Chiang et al., 2000) and also a 
failure to induce T-cell tolerance (Jeon et al., 2004). 
 
1.5.4 The physiological function of Cbl-3 
Cbl-3 differs from c-Cbl and Cbl-b both in expression pattern, structure and physiological 
functions. It is mainly espressed in epithelial tissues lining the small intestine, colon, prostate, 
adrenal gland and salvary gland (Huang, 2010; Keane et al., 1999). Cbl-3 exhibits normal E3 
ligase activity, despite its truncated structure. However, in contrast to c-Cbl and Cbl-b, Cbl-3 
deficiency in mice does not seem to have any effect on the phenotype in epithelial tissues 
(Griffiths et al., 2003).  
 
1.5.5 c-Cbl and Cbl-b in EGFR trafficking  
c-Cbl and Cbl-b appear to have distinct roles in regulation of several receptors, especially 
immune receptors. c-Cbl regulates the internalization and degradation of components of T 
cell-receptors and B cell-receptors, while Cbl-b regulates the level of specific signaling 
molecules involved in T cell-receptor and B cell-receptor signaling (Badger-Brown et al., 
2012; Shao et al., 2004; Thien and Langdon, 2005). Additionally, it has been reported that c-
Cbl and Cbl-b has different functions in the IgE-receptor FcεRI signaling, by which Cbl-b 
negatively regulates mast cell degranulation significantly more than c-Cbl (Zhang et al., 
2004).  
 
However, except for some minor differences in their protein length and structure, c-Cbl and 
Cbl-b seems to perform the same regulatory mechanism in terms of EGFR ubiquitination and 
downregulation. Knockout of only one of them does not have any effect on EGFR 
downregulation, while knockout or downregulation of both of the Cbl´s have a significant 
negative effect on downregulation and internalization of the receptor (Pennock and Wang, 
2008).  
 
Upon EGFR activation, c-Cbl and Cbl-b can bind both directly and indirectly to specific 
phosphotyrosine residues on the receptor. Cbl can bind directly to the pY1045 site in EGFR 
through their SH2-domain in the TKB domain and at the same time recruit other proline rich 
binding proteins, like the adaptor protein Cbl-interacting protein of 85 kDa (CIN85), which is 
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bound through its SH3-domain to the proline rich region in Cbl. The multidomain structure of 
CIN85 makes it able to also interact with a variety of other proteins, which are involved 
several important processes such as regulation of RTK signaling, apoptotic signaling and T 
cell functions (Kowanetz et al., 2003; Szymkiewicz et al., 2002). Of note, CIN85 has been 
demonstrated to constitutively interact with the ESCRT-protein Hrs (Ronning et al., 2011). 
Additionally, Cbl can also bind indirectly to the pY1068 and pY1086 residues on the EGFR 
through the interaction of their proline rich domain with the SH3-domains in Grb2. Together, 
Grb2 and Cbl bind to distinct phosphotyrosine sites on the receptor and cooperate in order to 
mediate rapid internalization and downregulate the receptor signaling (Levkowitz et al., 
1999; Waterman et al., 2002). Binding of Cbl to pY1045 is crucial for sorting of the ligand 
bound EGFR towards lysosomal degradation, suggested by the findings that mutation in this 
binding site leads to decreased degradation of receptor in lysosomes and increased recycling 
(Grovdal et al., 2004). On the other hand, indirect binding of Cbl to pY1068 and pY1086 is 
essential for internalization rather than receptor trafficking towards lysosomal degradation 
(Huang and Sorkin, 2005). Taken together, distinct binding patterns of Cbl to the receptor 
differently affects EGFR fate.  
 
Although c-Cbl and Cbl-b appear to have overlapping functions in EGFR regulation, some 
differences have been reported. c-Cbl has been stated to be recruited earlier to the EGF 
receptor than Cbl-b, and Cbl-b seems to have prolonged association with the receptor when 
compared to c-Cbl. In these experiments c-Cbl appears to be strongly recruited after 15 
minutes and Cbl-b after 30 min, by which Cbl-b seems to be associated with the receptor for 
at least 4 hours (Pennock and Wang, 2008). In addition, Pennock and Wang (2008) reported 
that Cbl-b may have additional binding sites in EGFR compared to c-Cbl. By using various 
forms of EGF receptors truncated in the C-terminal part transfected into 293T cells, Cbl-b, 
but not c-Cbl was found to bind truncated receptors containing amino acids 1-1044 or 1-958, 
lacking the identified Cbl binding site, pY1045, and the Grb2 binding sites, pY1068/1086. 
This suggested that Cbl-b binds to these constructs at sites not used by c-Cbl (Pennock and 
Wang, 2008). It has also been proposed that the UBA domain in Cbl-b can bind ubiquitinated 
proteins in contrast to c-Cbl. In 293T cells co-transfected with HA epitope tagged ubiquitin 
and c-Cbl or Cbl-b, the molecular weight of ubiquitinated proteins co-immunoprecipitated 
with each of the Cbls were compared. It was observed that considerable more ubiquitinated 
proteins with higher molecular weight was precipitated with overexpression Cbl-b, but not 
with c-Cbl (Davies et al., 2004). Further, c-Cbl and Cbl-b might have different roles in the 
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EGFR induced signaling, as overexpression of Cbl-b, but not c-Cbl, appears to inhibit the cell 
growth mediated by EGF-induced signaling in 32D cells overexpressing EGFR (Ettenberg et 
al., 1999).  
 
Taken together, these reported differences between c-Cbl and Cbl-b in EGFR regulation give 
rise to further questions about their individual and cooperative functions. As different 
recruitment sites for Cbl in EGFR has different regulatory functions and the finding that Cbl-
b may have other binding sites in EGFR when compared to c-Cbl, could indicate a more 
diverse regulatory function of Cbl-b compared to c-Cbl, such as in intracellular trafficking 
and cellular growth. 
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2 Aim of study 
 
The Cbl family members c-Cbl and Cbl-b share the same functional structure and their 
ubiquitin ligase activity has been studied for years, of which c-Cbl has been most in focus. 
Nevertheles, studies on Cbl-b have shown that, in contrast to c-Cbl it is important in negative 
regulation of intracellular signaling leading to apoptosis and also appear to have an ubiquitin 
binding domain that is able to bind ubiquitinated proteins unlike c-Cbl. Even though both c-
Cbl and Cbl-b are mainly expressed in the same cell types, they appear to have some different 
essential functions, exemplified in the importance of c-Cbl in male fertility (El Chami et al., 
2005), and requirement of Cbl-b in the normal T-cell response (Bachmaier et al., 2000). 
Another comparative study between c-Cbl and Cbl-b proposed that Cbl-b had additional 
binding sites in EGFR and that they displayed different time of recruitment, by which it was 
demonstrated that c-Cbl was the first to bind EGFR followed by an overlap with Cbl-b that 
appeared to have a prolonged association with the receptor (Pennock and Wang, 2008).  
However, despite studies that have demonstrated differences in their functions, few other 
published studies have compared their activity and function in EGFR regulation. 
 
The overall aim of this study is to look into the functions of c-Cbl and Cbl-b in EGFR 
regulation, by comparing their recruitment to the EGFR upon EGF stimulation and their 
intracellular trafficking to early endosomes.  
 
The approach was the following: 
- To study the colocalizations of c-Cbl, Cbl-b and EGF using live imaging 
- To study the colocalization of c-Cbl and Cbl-b to early, Hrs-positive endosomes  
- Comparison of binding of c-Cbl and Cbl-b to the EGFR by use of biochemical 
techniques 
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3 Materials and methods 
 
3.1 Constructs 
 
3.1.1 Plasmids and expression vectors 
c-Cbl and Cbl-b were subcloned from pDsRed-momomer-C1 vector into a pcDNA3 vector 
containing the gene encoding the fluorescent tag mCherry by PCR-amplification of c-Cbl and 
Cbl-b from pDsRed-c-Cbl and pDsRed-Cbl-b, followed by restriction cutting using NotI and 
XhoI and ligation into the pcDNA3-mCherry vector. A schematic map over pDsRed-
monomer-C1 and pcDNA3 are illustrated in figure 3-1 A and B, respectively.  
 
A           B  
 
 
 
Figure 3-1. Schematic map of expression vectors pDsRed-Monomer-C1 and pcDNA3.  
 
Other contstructs were also used in this study for both biochemical experiments and live cell 
imaging. An outline of the different plasmids are listed in table 3-1. 
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Table 3-1. List of expression contructs used in this study 
Plasmid Gene Vector Source 
pEGFP-c-Cbl c-Cbl pEGFP-C1 (Clontech) I.H. Madshus* 
pcDNA3-mCherry-c-Cbl c-Cbl pcDNA3-mCherry 
(Progida et al., 2012) 
 
Benedicte Semb Hagen 
pDsRed-monomer-c-Cbl c-Cbl pDsRed-monomer-C1 
(Clontech) 
I.H. Madshus* 
pEGFP-Cbl-b Cbl-b pEGFP-C1 (Clontech) I.H. Madshus* 
pcDNA3-mCherry-Cbl-b Cbl-b pcDNA3-mCherry 
(Progida et al., 2012) 
Benedicte Semb Hagen 
pDsRed-monomer-Cbl-b Cbl-b pDsRed-monomer-C1 
(Clontech) 
I.H. Madshus* 
mRFP-Hrs Hrs mRFP (Campbell et al., 
2002) 
Frode M. Skjeldal** 
* Inger Helene Madshus, Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway 
**Frode Miltzow Skjeldal, Department of Biosciences, University of Oslo, Oslo, Norway 
 
 
3.2 DNA techniques 
 
3.2.1 PCR 
The Cbl constructs were amplified by Polymerase Chain Reaction (PCR) of the Cbl sequence 
in the pDsRed-plasmid constructs using gene specific primers containing restriction sites for 
the restriction enzymes NotI and XhoI, which were located upstream and downstream the Cbl 
sequences respectively (table 3-2). Phusion High Fidelity DNA Polymerase (New England 
Biolabs, Ipswich, England) was used for amplification. The PCR mixture was prepared 
according to the enzyme manufactorer´s protocol.  
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Table 3-2. List of primers and restiction enzymes used in this study * 
Name of primer Tm Primer sequence 
c-Cbl forward/NotI  82 °C 5´ GAAGCGGCCGCAATGGCCGGCAACGTGAAGAA 3´ 
c-Cbl reverse/XhoI  72 °C 5´GAACTCGAGCTAGGTAGCTACATGGGCAGGAGAAGAAA 
3´ 
Cbl-b forward/NotI  74 °C 5´ GAAGCGGCCGCAATGGCAAACTCAATGAAT 3´ 
Cbl-b reverse/XhoI  66 °C 5´ GTTCTCGAGCTATAGATTTAGACGTGGGGATACTG 3´ 
*Restriction enzyme sites are written in bold 
 
The PCR reaction programme used started with one denaturation step at 95 °C / 2 minutes, 
followed by 30 cycles of denaturation at 95 °C /20 seconds, annealing at 60 °C /20 seconds 
and amplification at 72 °C /6 minutes. The whole PCR cycle was ended by a final elongation 
at 72 °C /3 minutes. An overview of the PCR setup is described in table 3-3. 
 
 
Table 3-3. PCR setup 
Stage Duration Temperature (C) Cycles 
Initial denaturation 
2min 95 1 
Denaturation 
20s 95  
Annealing 
20s 60 30 
Amplification 
6min 72  
Final elongation 
3min 72 1 
 
 
3.2.2 Agarose gel electrophoresis 
DNA fragments and digested vector were separated in 1 % agarose gels. The agarose gel was 
prepared by dissolving 0,5 g TopVision Agarose (Thermo Scientific, Waltham, USA) and 5 
l Ethidium Bromide in 50 ml 1 x Tris-acetate-EDTA buffer (TAE, 40 mM Tris-acetate, 1 
mM EDTA). 6 x sample buffer was added to the individual DNA samples before they were 
separated on gel using a 10K DNA ladder (Thermo Scientific, Waltham, USA) as a reference. 
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The agarose gel electrophoresis was performed in 1 x TAE buffer at 5 V per cm of the gel in 
45 minutes. The DNA bands was detected by exposure to UV light in a UV Transilluminator 
(UVP, CA, USA). 
 
DNA-fragments and digested vector were purified from the agarose gel using QIAquick Gel 
Extraction Kit (QIAgen, Hilden, Germany) following the manufactoter´s manual.  
 
3.2.3 Restriction digestion and ligation of DNA fragments 
The PCR products (purified from gel) and the vectors were restriction digested with the 
restriction enzymes XhoI and NotI with an appropriate buffer for double digestion. All 
enzymes and buffers were supplied by (New England Biolabs). The digestion was completed 
at 37 °C over night (16 hours).  
 
The vector was run on gel and purified as described in the previous section using QIAquick 
Gel Extraction Kit while the digested PCR-fragments were purified with E.Z.N.A® Cycle 
Pure Kit (Omega Biotek, Nocross, GA, USA). 
 
Digested c-Cbl and Cbl-b fragments were ligated into the digested pcDNA3-mCherry vector 
at room temperature (RT) for 2 hours utilizing 1 l T4 DNA ligase and 1 l 10 x T4 DNA 
ligase buffer (both New England Biolabs) in a final volume of 10 µl. The ratio of PCR 
fragment to vector was 5:1. 
 
3.2.4 Bacterial transformation  
For amplification of  plasmid DNA, CaCl2 competent E.coli Top10F cells were used for 
transformation. 200 l cells were thawed on ice and incubated with 1 g plasmid DNA on ice 
for 30 minutes. They were then heat shocked at 42 °C  in water bath for 2 min, followed by 
incubation on ice for 2 minutes. 1 ml Lysogeny broth (LB) medium (prewarmed to 37 °C) 
was then added before incubation for 1 hour at 37 °C on a heating block. Next, the cells were 
pelleted by centrifugation at  4000 rpm and 90 % of the supernatant was removed before 
resuspension of the bacteria in the remaining solution. Transformed bacteria were then plated 
on an agar plate containing 100 g/ml ampicillin or 250 g/ml kanamycin, depending on the 
selection marker of the plasmid, and incbated over night in an incubator at 37 °C. Antibiotic 
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resistant clones were then picked and grown in 100 ml LB medium containing 100 mg/ml 
ampicillin or 250 mg/ml kanamycin in an incubator at 37 °C over night followed by midiprep 
purification.  
 
For amplification of plasmids from a ligation mixture, XL 10-Gold Ultracompetent Cells 
(Agilent Technologies, CA, USA) were used for transformation. 100 l cells were thawed 
and incubated on ice with 4 l -mercaptoethanol, included in the kit, for 10 minutes. 5 l of 
the ligation mixture was added to the bacteria and they were further incubated on ice for 30 
minutes. The cells were then heat shocked at 42 °C in water bath for 30 seconds followed by 
incubation on ice for 2 minutes. 900 l 42 °C Super Optimal broth with Catabolite repression 
medium were added to the cells, and incubated in an at 37 °C incubator with shaking for 1 
hour. The bacteria were then pelleted, resuspended in 200 l LB medium and plated on agar 
plates containing 100 g/ml ampicillin and incubated at 37 °C over night. pUC18 control 
plasmid was used as control. The ampicillin resistent clones were then grown in 1,5 ml LB 
medium for miniprep purification 
 
3.2.5 Plasmid purification 
E.Z.N.A.® Plasmid Mini Kit I (Omega Bio-Tek, PA, USA) and Wizard Plus Midipreps 
DNA Purification System (Promega, WI, USA) was used for small-scale and medium-scale 
plasmid DNA purification, respectively. Small-scale plasmid DNA was used for purification 
of plasmids from bacterial cells after cloning and ligation, while medium-scale plasmid DNA 
was used for large scale purification of plasmids.  The purification was performed using the 
manufacturer´s manual with supplemented solutions and reagents.  
 
3.2.6  Sequencing 
Primers used for sequencing was constructed in Webprimer 
(http://www.yeastgenome.org/cgi-bin/web-primer) with 600 base pairs between  alignment of 
the primers. The pcDNA3-mCherry-Cbl constructs were sequenced by GATC Biotek 
(Konstanz, Germany). The program CLC sequence viewer 
(http://www.clcbio.com/products/clc-sequence-viewer) was used for the sequence alignment. 
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3.3 Cell techniques 
 
3.3.1 Cell lines and cell culture 
The human epithelial cervix adenocarcinoma cell line HeLa stabily transfected with a 
plasmid encoding CdCl2-inducable expression of invariant chain (Ii), pMEP4-Ii, (HeLa Ii) 
and wt HeLa cells were used in this study. HeLa cells were grown in Dulbeccos Modified 
Eagles Medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10 % fetal calf 
serum (BioSera, Boussens, France), 2 mM L-glutamine, 25 U/ml penicillin, 25 g/ml 
streptomycin (all from PAA Laboratories, Pashing, Austria) and incubated in 5 % CO2 in a 
37 °C incubator. The HeLa Ii cells were grown in DMEM supplemented with 10 % fetal calf 
serum, 0,15 mg/ml Hygromycin B (Duchefa Biochemie BV, Haarlem, Netherlands), 2 mM 
L-glutamine, 25 U/ml penicillin, 25 g/ml streptomycin and incubated in 5 % CO2 in a 37 °C 
incubator. The expression of Ii was induced by incubation with 2,5 M CdCl2 over night (16-
18 hours). An overview of the cell density seeded for each experiment are included in table 3-
4 and 3-5. 
 
Table 3-4. Cell density for experiments two days after seeding. HeLa (1,5 x 10
5 
cells/cm
2
) 
and HeLa Ii (4,5 x 10
5 
cells/cm
2
) 
Cells Dish Area Cells/dish Producer Experiment 
HeLa 3,5 cm glass 
bottom dishes 
8 cm
2 
1,20 x 10
5
 MatTek Corp., 
MA, USA 
Live cell imaging 
HeLa Ii 3,5 cm glass 
bottom dishes 
8 cm
2
 3,60 x 10
5
 MatTek Corp., 
MA, USA 
Live cell imaging 
HeLa 6 cm 21,5 cm
2
 3,22 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Western blot 
HeLa Ii 6 cm 21,5 cm
2
 9,77 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Western blot 
HeLa Ii 6 well plate 9,5 cm
2
 4,28 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Immunoprecipitation 
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Table 3-5. Cell density for experiments  three days after seeding. HeLa Ii (22,5 x 10
5 
cells/cm
2
) and HeLa (7,5 x 10
5 
cells/cm
2
)  
Cells Dish Area Cells/dish Producer Experiment 
HeLa 3,5 cm glass 
bottom dishes 
8 cm
2 
0,6 x 10
5
 MatTek Corp., 
MA, USA 
Live cell imaging 
HeLa Ii 3,5 cm glass 
bottom dishes 
8 cm
2
 1,8 x 10
5
 MatTek Corp., 
MA, USA 
Live cell imaging 
HeLa 6 cm 21,5 cm
2
 16,25 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Western blot 
HeLa Ii 6 cm 21,5 cm
2
 4,85 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Western blot 
HeLa Ii 6 well plate 9,5 cm
2
 2,14 x 10
5
 Nunclon™Surface, 
NUNC, Roskilde, 
Denmark 
Immunoprecipitation 
 
 
3.3.2 Transient transfection 
HeLa cells were seeded as described above and transfected the day before the experiment 
with one or two of the constructs listed in table 3-6 using Lipofectamine 2000 (Invitrogen, 
OR, USA). At the day of transfection, growth medium was removed and the cells were 
washed tree times with Phosphate buffered saline (PBS) before addition of DMEM w/o 
antibiotics, with 2 mM L-glutamine and 10 % fetal calf serum. 
 
Lipofectamine2000 was first mixed with Opti-MEM® (Invitrogen) and incubated for 5 
minutes. In another tube, DNA was mixed with Opti-MEM
®
. After incubation, the 
Lipofectamine2000 solution was mixed with the DNA-solution and further incubated for 
20 minutes before adding the mixture to the cells. The amount of Opti-MEM
®
, 
Lipofectamine2000 and DNA are listed in table 3-6. For cotransfections of c-Cbl and Cbl-b 
the two plasmids were mixed by a ratio 1:1, and for cotransfection of Hrs and either of the 
Cbl constructs the plasmids were similarily mixed by a ratio of 1:3. 
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Table 3-6. Overview of the Lipofectamine2000 transfection mixture. 
Cell culture plate Volum of 
plating medium 
Total DNA  Lipofectamine Opti-MEM
®
 
6 well plate  2 ml 4 µg 2,25 µl 2 x 250 µl 
3,5 cm dish 2 ml 2-4 µg  2,25 µl 2 x 250 µl 
6 cm dish 5 ml 8 µg 3 µl 2 x 500 µl 
 
 
3.4 Protein techniques 
 
3.4.1 Cell lysis 
The cells were chilled on ice and washed three times with cold PBS and lysed in cold lysis 
buffer (Supplementary, table S2) for 15 minutes. The lysates were then transferred to 
prechilled eppendorf tubes and centrifuged at 13000 x g at 4 °C  for 15 minutes  to remove 
cell nuclei and debris. The supernatant containing the proteins were transferred to new 
prechilled eppendorf tubes. 100 l and 200 l lysis buffer was used in 6 well plates and 6 cm 
dishes, respectively.  
 
Cells were serum starved by incubation with DMEM (Invitrogen) supplemented with 2 mM 
L-glutamine, 25 U/ml penicillin, 25 g/ml streptomycin for 4 hours before stimulation with 
100 ng/ml EGF in phenol red-free HEPES-supplemented DMEM (Invitrogen) containing 25 
U/ml penicillin, 25 g/ml streptomycin and  0.1 % bovine serum albumine (Sigma Aldrich, 
MO, USA) 
 
3.4.2 SDS-PAGE and Western blotting 
6 x sample buffer (Supplementary, table S6) was added to the protein samples prepared for 
Western blot, as described above, and boiled at 95 °C in 5 minutes to denature the proteins. 
20 µl of the samples were loaded on a 10 % gel (Thermo Scientific Precise Protein Gels, 
Pierce, Rockford, IL, USA) and the proteins were separated at 100 V for 70 minutes in 1 x 
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HEPES running buffer (Supplementary, table S3). 5 l of the prestained standard Precision 
Plus Protein Kaleidoscope (Bio-Rad, Hercules, CA, USA) was used a a protein size 
marker. 
 
Immobilion Polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA) 
were pre-treated in methanol for 20 seconds, followed by incubation in dH2O for 2 minutes 
and in 1 x Tris-Glycine Transfer buffer (Supplementary, table S4) for 5 minutes. The gel with 
the separated poteins and PVDF-membrane was assembled in an assembly cassett with the 
membrane facing the cathode. The separated proteins were transferred onto the PVDF-
membranes at 100 V for 60 minutes at 4 °C in 1 x Tris-Glycine Transfer buffer. 
 
The membranes were washed at room temperature for 5 minutes in Tris-buffered saline 
(TBS) (Supplementary, table S5) containing 0,05 % Tween-20 (TBS-T), followed by 
blocking in TBS-T with 5 % blotting grade non-fat dry milk (Bio-Rad, Hercules, CA, USA) 
for 30 minutes. The membranes were then incubated with primary antibody diluted in TBS-T 
with 1% blotting grade non-fat dry milk either over night at 4 °C or for 1 hour at RT. The 
membranes were washed 3 x 10 times with TBS-T after incubation with primary antibody 
followed by blocking in 30 minutes. Further, the membranes were incubated with secondary 
Horseradish peroxidase (HRP)-conjugated antibody diluted in TBS-T with 1 % blotting grade 
non-fat dry milk either over night at 4 °C or for 1 hour at RT. Last, the membranes were 
washed 3 x 10 times with TBS-T and incubated in SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific, Pierce, Rockford, USA) to generate a luminiscence 
signal. The luminescent signal was detected on Kodak Image Station 4000R (Carestream 
Health Inc., NY, USA) and the intensity of the bands were measured using the Carestream 
Molecular Imaging program (Carestream Health, Inc., NY, USA). 
 
3.4.3 Immunoprecipitation 
Magnetic Dynabeads Protein G (Invitrogen) were used for immunoprecipitation (IP) A 
magnet was used to remove supernatant from the beads throughout the protocol.  
 
50 l of beads were used per IP. Supernatant was removed from the beads before they were 
incubated with 200 l PBS containing 0,02 % Tween-20 (PBS-T) and 1 g of primary 
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antibody under rotation at RT for 60 minutes to allow the Dynabeads to bind the antibody. 
After incubation, the eppendorf tubes were placed on a magnet and the supernatant was 
removed and beads washed three times with PBS-T. 
 
10 l of the cell lysates were transferred to new eppendorf tubes and 2 x sample buffer 
(Supplementary, table S7) added to these protein samples representing the total cell lysates 
and boiled at 95 °C for 5 minutes to denature the proteins. The rest of the cell lysate were 
incubated with the antibody coupled Dynabeads from above, under rotation at 4 °C for 60 
minutes.  
 
After incubation, the Dynabeads were placed on magnet and supernatant was removed. The 
beads were then washed three times with 200 l lysis buffer. Finally, the beads were 
resuspended in 20 l 2 x sample buffer (Supplementary, table S7) and boiled at 95 °C  for 5 
minutes before being loaded onto SDS-PAGE-gels and analyzed by Western Blotting as 
described above. 
 
3.4.4 Antibodies 
All antibodies used in this study are listed in supplementary, table S1. 
 
3.5 Imaging techniques 
HeLa and HeLa Ii cells were seeded on 3,5 cm glass bottom dishes and left to adhere for 24 
or 72 hours before being transiently transfected with DNA of interest using 
Lipofectamine2000, as previously described. At the day of the live imaging experiment, the 
cells were washed 3 times with 1 x PBS prewarmed to 37 °C before adding phenol red free, 
HEPES-supplemented DMEM containing 10 % fetal calf serum. EGF conjugated with Alexa 
647 (Invitrogen) was added to cells under the microscope while imaging (final concentration 
100 ng/ml), in order to initiate activation and internalization of the EGF receptor. The cells 
were maintained inside a 37 °C chamber during the imaging. 
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The live cell imaging was carried out using PlanApo 60x/1,42 oil objective on an Olympus 
IX-71 microscope (Olympus, Hamburg, Germany), set up with a CSU22 Spinning Disk 
confocal unit (Yokogawa, Tokyo, Japan) and an iXonEM+EMCCD camera (Andor, Belfast, 
UK). The fluorochromes were excited with an Argon laser emitting 488 nm, 559 nm or 647 
nm. All live imaging experiments were excecuted with one frame per 5 or15 seconds for 12-
87 minutes, and the images were prepared using Andor iQ 1.8.1 software and ImageJ (NIH, 
Bethesda, MD). 
 
3.5.1 Image analysis 
The images were analysed in ImageJ. The area around the cell was subtracted to give the 
region of interest (ROI). The area in ROI was subjected to background subtraction using the 
built-in rolling-ball algorithm. The images were thresholded so the structures positive for 
Cbl, EGF or Hrs could be detected and the number of pixels representing the structures were 
quantified. 
 
The colocalizations were analysed using the colocalization plug-in, which superimposes the 
pixels from the two respective thresholded images and quantifies the number of colocalized 
pixels in the ROI. Subsequently, the number of pixels showing colocalization was expressed 
as a proportion of the total thresholded pixels for each of the given proteins, by dividing the 
number of pixels showing colocalization by the number of thresholded pixels for each of the 
individual channels at each time point.  
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4 Results 
 
4.1 Construct design and characterization of cell lines 
In order to optimize the visualization of red fluorescence protein tagged c-Cbl and Cbl-b 
under live imaging, c-Cbl and Cbl-b were cloned into the pcDNA3-mCherry vector as 
mCherry is a more photostable and brighter protein than DsRed (Shaner et al., 2005). First, a 
gene encoding Rab7b originally included in pcDNA3-mCherry was removed by restriction 
digestion using NotI and XhoI. PCR-amplified Cbl-sequences were digested using the same 
restriction enzymes (NotI and XhoI) and subcloned into the digested pcDNA3-mCherry 
construct, downstream of the mCherry gene and cytomegalovirus (CMV) promoter (figure 4-
1).  
                            
 
Figure 4-1: Illustration of the subcloning of the Cbl-gene from pDsRed-monomer-C1 into pcDNA3-
mCherry. The gene encoding Rab7b was removed from the pcDNA3-mCherry-Rab7b plasmid by restriction 
digestion using the enzymes NotI and XhoI. The Cbl-sequences were amplified by PCR using primers 
containing the same  restriction sites as used for pcDNA3-mCherry-Rab7b. The amplified Cbl-sequences were 
cut by NotI and XhoI and ligated into the pcDNA3-mCherry vector. 
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To identify plasmids containing the correct Cbl-insert, several clones of the pcDNA3-
mCherry-Cbl constructs were digested with NotI and XhoI, as described in section 3.2.3. The 
digestion reactions were loaded on a 1% agarose gel to identify plasmids containing the Cbl 
insert (figure 4-2 A and B). Several of the plasmids showed a band of correct sizes, around 
3000 base pairs, representing the Cbl insert. The plasmids displaying correct band sizes were 
verified by sequencing, as described in section 3.2.6. To verify that expression of mCherry-c-
Cbl and mCherry-Cbl-b were induced properly from the mCherry-plasmids, HeLa Ii cells 
were transiently transfected with pcDNA3-mCherry-c-Cbl or pcDNA3-mCherry-Cbl-b 
before lysis and blotting against antibodies specific for c-Cbl and Cbl-b (figure 4-2 C and D). 
Non-transfected HeLa Ii cells expressing only endogenous c-Cbl and Cbl-b were used as 
negative control, while HeLa Ii cells transfected with EGFP-Cbl or DsRed-Cbl were used as 
a positive control. The cells transfected with mCherry-Cbl showed bands at similar size as for 
the positive controls, indicating that the constructs were correctly expressed in the cells. 
 
 
A        B   
               
C        D 
                       
 
Figure 4-2: Verification of plasmids expressing mCherry-Cbl. A and B: Identification of plasmids 
containing the Cbl insert. Several different clones of  pcDNA3-mCherry-c-Cbl (A) and pcDNA3-mCherry-Cbl-
b (B) were digested with NotI and XhoI in appropriate buffers at 37 °C over night. 6 x sample  buffer was added 
to the digested plasmids before being loaded onto a 1 % agarose gel. A band of approximately 3000 bp, the 
correct size of the Cbl-inserts, could be detected in several clones. C and D: Expression of mCherry-Cbl in Hela 
Ii cells. HeLa Ii cells were transiently transfected with pcDNA3-mCherry-Cbl-plasmids, using pEGFP-Cbl- and  
6000 bp 
3000 bp 
6000 bp 
3000 bp 
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pDsRed-Cbl constructs as positive controls. Non-transfected cells were used as a negative control. The cells 
were lysed and the proteins were separated on SDS-PAGE. The proteins were transferred to a PVDF membrane 
blotted with antibodies specific for c-Cbl and Cbl-b, respectively. The membranes were blotted with an antibody 
against Tubulin as loading control. Expression of both mCherry-c-Cbl (C) and  mCherry-Cbl-b ccould be 
detected (D). 
 
 
4.1.1 Imaging of mCherry-Cbl 
As a final control, HeLa Ii cells transfected with mCherry-c-Cbl or mCherry-Cbl-b were 
analyzed under confocal microscope. Unfortunately, the expression of the mCherry-Cbl 
constructs appeared to cause aggregation of the mCherry-Cbl proteins in the majority of the 
transfected cells (figure 4-3 A and B) and the mCherry constructs did not translocate to the 
EGFR upon EGF addition (confocal imaging, data not shown). For this reason, DsRed was 
utilized as red fluorescent tag for Cbl in further experiments. 
 
A       B 
 
Figure 4-3. Confocal microscopy of mCherry-Cbl. HeLa Ii cells seeded onto 3,5 cm dishes and transiently 
transfected with either  mCherry-c-Cbl (A) or mCherry-Cbl-b (B) over night. The cells were imaged at 37 °C 
using a Spinning Disc confocal microscope with lasers emitting fluorescent light at 555 nm wavelength. 
 
 
4.1.2 Cell lines 
HeLa Ii were initially intended to be used for live imaging due to their ability to express Ii 
through its CdCl2 inducable promoter. Ii expression induces formation of enlarged 
endosomes, which makes it easier to visualize different domains on endosomes and therefore 
if two proteins on the same endosome actually colocalize on the same endosomal domains. 
However very few cells containing Ii induced enlarged endosomes expressed the transfected 
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Cbl constructs. In most of the cells expressing the Cbl-constructs, enlarged endosomes could 
not be detected. Additionally, Hela Ii cells with induced enlarged vesicles appeared to be 
particularly sensitive towards live imaging. For this reason, wt HeLa cells were also used in 
the following experiments. Both HeLa Ii and HeLa cells express EGFR, c-Cbl, Cbl-b and Hrs 
endogenously (figure 4-4).  
 
 
   
 
4.2 c-Cbl and Cbl-b show similar colocalization  
characteristics with EGF 
To investigate the trafficking of c-Cbl and Cbl-b towards activated EGFR, HeLa cells were 
transiently cotransfected with DsRed-c-Cbl and EGFP-Cbl-b and imaged under a Spinning 
Disc confocal microscope. Hela cells endogenously expressing EGFR were stimulated with 
100 ng/ml Alexa 647-tagged EGF. EGFR ligand addition induced a distinct recruitment of 
DsRed-c-Cbl and EGFP-Cbl-b to EGF, at which it was much easier to detect Cbl-b regardless 
of the tag used, suggesting that there could be a stronger recruitment of Cbl-b than c-Cbl to 
the EGFR (figure 4-5, movie S1 and data not shown). However, despite the weaker signal 
from DsRed-c-Cbl on EGF positive endosomes, we could observe a similar recruitment 
pattern of c-Cbl and Cbl-b.  
 
 
 
Figure 4-4: Endogenous expression of EGF receptor, c-Cbl, Cbl-b 
and Hrs in HeLa Ii and HeLa cells.  
HeLa Ii (without or with Ii induction) and HeLa cells were lysed and 
the proteins were separated on SDS-PAGE. The proteins were 
transferred onto a PVDF membrane and blotted with antibodies 
specific for EGFR, c-Cbl, Cbl-b, Hrs, and Ii. The membranes were 
blotted with an antibody against Tubulin as a loading control.  
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Figure 4-5: Trafficking of c-Cbl and Cbl-b with EGF. HeLa cells were transiently cotransfected with DsRed-
c-Cbl and EGFP-Cbl-b and stimulated with 100 ng/ml Alexa 647-tagged EGF under live imaging at 37 °C using 
Spinning Disc confocal microscopy with lasers emitting fluorescent light at 488, 555 nm and 647 wavelength.  
 
 
 
The pixels representing c-Cbl, Cbl-b and EGF structures were analyzed, and the amount of 
the given proteins in the colocalized area was further quantified as described in section 3.5.1. 
The quantifications showed that when measuring the total number of colocalized pixels in the 
cell, colocalization of c-Cbl and Cbl-b with EGF both started after around 3 minutes, 
followed by a plateu (figure 4-6 A and C). However, the weak signal from DsRed-tagged c-
Cbl lead to high pixel background and therefore less certainty regarding c-Cbl measurements. 
When quantifying the fraction of each protein that colocalized with an other protein, based on 
number of pixels (figure 4-6 B and D), an increased proportion of pixels representing c-Cbl 
DsRed-c Cbl EGFP-Cbl-b F Alexa 647 rge 
 0 
   5 min
  
             10 i  
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on EGF structures could be detected over time, coinciding with increased recruitment to 
EGFR. However, it was difficult to establish the pattern due to the weak signal from c-Cbl. 
An increased proportion of pixels representing Cbl-b on EGF structures could be detected at 
early time points followed by a plateu, which was as expected when compared to the plateu 
in figure C. The proportion of EGF colocalizing with c-Cbl or Cbl-b over time was low. This 
could be due to a much larger size of the EGF structures than the Cbl-stuctures, which would 
lead to more EGF pixels than Cbl pixels on what that supposedly is the same endocytic 
vesicle. Another explanation could be saturation of the cell with Alexa 647-tagged EGF 
during stimulation, which might lead to alternative endocytic pathways. 
 
 
 
Figure 4-6: Quantification of colocalization of c-Cbl and EGF, and Cbl-b and EGF. Quantification of live 
imaging in figure 5-5 (movie S1), analyzed in ImageJ. 
A and C: Percentage of colocalized pixels measured as number of pixels showing colocalization of c-Cbl and 
EGF (A) or Cbl-b and EGF (C) out of total number of pixels in ROI. B and D: Percentage colocalization 
measured as fraction of colocalized pixels relative to the total number of c-Cbl or EGF pixels (B) or number of 
Cbl-b or EGF (D) pixels in the ROI. The analysis was based on one experiment.  
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4.3 Binding of c-Cbl and Cbl-b to EGFR show a different 
efficiency of recruitment 
The previous imaging experiment could indicate that although both Cbls seem to localize 
together with EGF on endosomes at the same time points, Cbl-b was recruited more 
efficiently to the EGFR than c-Cbl, as the Cbl-b-structures were rapidly detected and gave a 
stronger signal than c-Cbl. To address this further, we investigated the recruitment of Cbl to 
EGFR upon EGFR activation by IP studies. In this experiment, HeLa Ii cells without Ii 
induction were transiently transfected with EGFP-c-Cbl or EGFP-Cbl-b and stimulated with 
EGF for the indicated time points. The time courses of the shown experiments were limited 
to 12 minutes, since it has previously been demonstrated that expression of Cbl leads to EGF 
receptor induced phosphorylation of Hrs within this period of time (Stern et al., 2007). Non-
stimulated cells were used as a negative control and stimulation for 60 min on ice as positive 
control to detect the total amount of c-Cbl and Cbl-b recruited to EGFR at the PM. EGFP-c-
Cbl and EGFP-Cbl-b were immunoprecipitated using antibody against GFP, and the 
immunoprecipitated proteins were further analyzed by Western blotting using antibodies 
specific for EGFR and GFP (figure 4-7 A). The intensity of the EGFR bands relative to the 
Cbl-bands were further quantified (figure 4-7 B). A higher proportion of EGFR was 
precipitated with Cbl-b over time than with c-Cbl, in accordance with the previous imaging 
experiment. Except for the more efficient recruitment of Cbl-b than c-Cbl to the EGFR, the 
tendency of the time courses were the same, also coinciding with the previous imaging 
experiment.   
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A 
       
 
B 
                                            
 
 
 
 
 
 
 
 
Figure 4-7: Recruitment of Cbl to EGFR. A: HeLa Ii cells were transiently transfected with either EGFP-c-
Cbl or EGFP-Cbl-b and stimulated with 100 ng/ml EGF for the indicated time points. The cells were lysed and 
immunoprecipitated with antibody against GFP. The samples were further blotted with antibodies specific for 
EGFR and GFP (Cbl and GFP). B: The intensities of the immunoreactive bands in A were analyzed in 
Carestream M1. The EGFR:Cbl ratios were calculated and normalized to the EGFR:Cbl-b value at 2 min for 
easier comparison. The data represents one representative out of four independent experiments showing similar 
results. 
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4.4 c-Cbl and Cbl-b colocalize with Hrs at similar time 
points 
Cbl has been reported to increase EGFR induced phosphorylation of Hrs, and this 
phosphorylation seems to be an important mechanism for correct trafficking of EGFR to 
lysosomes (Stern et al., 2007). After observing the more efficient recruitment of Cbl-b to 
EGFR when compared to c-Cbl, we further wanted to study if these differences could 
influence the trafficking of EGFR to Hrs positive endosomes. The trafficking was studied by 
transient cotransfections with either EGFP-c-Cbl and RFP-Hrs or EGFP-Cbl-b and RFP-Hrs. 
 
4.4.1 c-Cbl and Hrs 
In the experiment for c-Cbl, HeLa cells were transiently cotransfected with EGFP-c-Cbl and 
RFP-Hrs and stimulated with Alexa 647-tagged EGF under live imaging. Stimulation of 
EGFR with EGF showed a rapid recruitment of c-Cbl to EGF structures and they appeared to 
colocalize during internalization and intracellular trafficking (figure 4-8, movie S2).  
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Figure 4-8: Trafficking of c-Cbl to Hrs-positive vesicles after EGF stimulation. HeLa cells were transiently 
cotransfected with EGFP-c-Cbl and RFP-Hrs at 37 °C over night and stimulated with 100 ng/ml Alexa 647–
tagged EGF under live imaging using Spinning Disc confocal microscopy with lasers emitting fluorescent light 
at 488, 555 nm and 647 wavelength.  
 
 
We further analyzed colocalization over time for c-Cbl and EGF, c-Cbl and Hrs, and Hrs and 
EGF to better get a picture of the trafficking pattern. These data showed that colocalization of 
c-Cbl and EGF could be detected after 4 minutes (figure 4-9 A), indicating a rapid 
recruitment to EGF and correlating with the findings in c-Cbl and Cbl-b cotransfected cells 
(figure 4-6). Analyzing the proportion of c-Cbl involved in colocalization with EGF revealed 
that by 10 minutes after stimulation, there seems to be a plateu of the thresholded c-Cbl 
signal colocalizing with EGF (figure 4-9 B). Analysis of c-Cbl and Hrs demonstrated that the 
colocalization started around 4 minutes, at which there was a steady increase in the number 
of pixels representing c-Cbl that colocalized with Hrs (figure 5-9 C and D). Lastly, 
colocalization of Hrs and EGF appeared to start after 4 minutes, where there was a high 
proportion of pixels respresenting EGF colocalization with Hrs, suggesting a rapid trafficking 
pattern of EGFR to Hrs-positive early endosomes (figure 5-9 E and F). 
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Figure 4-9:  Colocalization of c-Cbl and EGF, c-Cbl and Hrs and Hrs and EGF. Quantification of live 
imaging in figure 4-8 (movie S2), analyzed in ImageJ. 
A: Percentage colocalization of c-Cbl and EGF in ROI. B: Percentage colocalization relative to the amount of c-
Cbl or EGF in the ROI. C: Percentage colocalization of c-Cbl and Hrs in ROI. D: Percentage colocalization 
relative to the amount of c-Cbl or Hrs in the ROI. E: Percentage colocalization of Hrs and EGF in ROI. F: 
Percentage colocalization relative to the amount of Hrs or EGF in the ROI. 
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4.4.2 Cbl-b and Hrs 
For experiments with Cbl-b, HeLa Ii cells with Ii induced enlarged endosomes were 
transiently cotransfected with EGFP-Cbl-b and RFP-Hrs and stimulated with Alexa 647 –
tagged EGF under live imaging (figure 4-10, movie S3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. The number of Cbl-b- and Hrs positive vesicles after EGF stimulation. HeLa Ii cells were 
transiently cotransfected with EGFP-Cbl-b and RFP-Hrs at 37 °C over night and stimulated with 100 ng/ml 
Alexa 647-tagged EGF under live imaging using Spinning Disc confocal microscopy with lasers emitting 
fluorescent light at 488, 555 nm and 647 wavelength. 
 
 
Further analysis showed that the colocalization of Cbl-b and EGF could be detected after 2 
minutes (figure 4-11 A), comparable to the findings in c-Cbl and Cbl-b cotransfected cells 
(figure 4-6). Further quantifications showed a rapid increase in the amount of Cbl-b pixels 
colocalizing with EGF pixels, also correlating with the observations in cells cotransfected 
with c-Cbl and Cbl-b. The small drop in the amount of Cbl-b that colocalized with EGF after 
4-5 min was not observed in the cells cotransfected with c-Cbl and Cbl-b and might simply 
be due to cell-to-cell variation, as quantifications are based on one cell only. Further, the 
 EGFP-Cbl-b   - rs  EGF Alexa 647 Merge 
 0 min 
 5 min 
           10 min 
Results 
 
45 
amount of EGF colocalizing with Cbl-b positive structures seemed to increase throughout the 
time course (figure 4-11 B). Colocalization of Cbl-b and Hrs showed a steady increase after 4 
minutes (figure 4-11 C), correlating with cells cotransfected with c-Cbl and Hrs (figure 4-9 
C). Analyzing the proportions of Cbl-b and Hrs colocalizing with each other revealed a 
similar time course pattern for both proteins (4-11 D). Lastly, Hrs and EGF showed 
colocalization after 4 minutes (figure 4-11 E), which is similar to c-Cbl in cells cotransfected 
with c-Cbl and Hrs (figure 4-9 E). Further, the analysis showed that there was a steady 
increase in the number of pixels showing colocalization of EGF and Hrs, suggesting a 
gradual trafficking of EGFR to early endosomes (figure 4-11 F). 
 
                 
 
Figure 4-11: Quantification of colocalization of Cbl-b and EGF, Cbl-b and Hrs and Hrs and EGF.  
The images from live imaging in figure 4-10 (movie S3) were analyzed in ImageJ.  
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A: Percentage colocalization of c-Cbl and EGF in ROI. B: Percentage colocalization relative to the amount of c-
Cbl or EGF in the ROI. C: Percentage colocalization of c-Cbl and Hrs in ROI. D: Percentage colocalization 
relative to the amount of c-Cbl or Hrs in the ROI. E: Percentage colocalization of Hrs and EGF in ROI. F: 
Percentage colocalization relative to the amount of Hrs or EGF in the ROI. 
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5 Discussion 
In this thesis I have investigated whether the two isoforms of the ubiqutin ligase Cbl, namely 
c-Cbl and Cbl-b, differently affect EGFR trafficking at early time points. c-Cbl and Cbl-b  
have been thought to have the same and overlapping function in the internalization and 
intracellular trafficking of activated EGFR. However some difference have been reported. Of 
note, c-Cbl seems to be recruited earlier to the receptor than Cbl-b and Cbl-b appears to have 
prolonged association with the receptor (Pennock and Wang, 2008). Further, Pennock and 
Wang (2008) proposed that Cbl-b has additional binding sites in the phosphorylated receptor  
compared to c-Cbl. Also, Cbl-b has been shown to regulate cellular growth through EGFR 
signaling to a larger extent than c-Cbl (Ettenberg et al., 1999). Taken together, even though c-
Cbl and Cbl-b display similar regulatory functions in EGFR internalization and trafficking, 
questions still remain about their individual functions. 
 
As Cbl proteins are essential for correct EGFR internalization and degradation following 
activation, we wanted to investigate whether any differences could be detected between c-Cbl 
and Cbl-b in EGFR trafficking by studying the recruitment of c-Cbl and Cbl-b to the 
activated EGFR and their trafficking to early endosomes. In order to investigate this, both 
biochemical assays and live imaging were conducted. HeLa Ii cells were initially selected for 
the experiments due to their ability to induce expression of Ii by addition of CdCl2, which in 
turn induces enlarged endosome. Hela Ii cells without induction of Ii were chosen for 
biochemical analysis, while Hela Ii cells with induced Ii-expression were chosen for live 
imaging, in order to avoid clonal differences. Endosomes contain many separate domains and 
two proteins on the same endosome might be localized to different microdomains. The Ii 
enlarged endosomes would make it easier to detect any possible colocations between two 
proteins on the same endosome by live imaging. However, there were several problems 
regarding the transient transfections and induction of expression of Ii. Wt HeLa cells were 
therefore also used and is the reason for different cell lines in the experiments. HeLa Ii cells 
appeared not display any different pattern of EGF endocytosis compared to HeLa 
(Supplementary, figure S1). The differences at early time points might be due to variations in 
EGFR expressions and thus different amount of EGF binding to the cells, which would result 
in differences in amount of pixels representing EGF structures. However, it seems that the 
pattern of internalization is essentially the same, as the curved appears to have the same peak. 
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Also, expression of endogenous Cbl-proteins and EGFR was the same in both cell lines 
(figure 4-4)  
 
To investigate the intracellular trafficking of c-Cbl and Cbl-b, HeLa cells were transiently 
cotransfected with DsRed-c-Cbl and EGFP-Cbl-b, and EGFR was stimulated with Alexa 
647-labeled EGF (figure 4-5). The analysis from live imaging showed that both c-Cbl and 
Cbl-b both appeared on EGF positive endosomes at the same time (figure 4-6). These data 
were verified by co-IP, which showed a similar recruitment pattern of c-Cbl and Cbl-b to 
EGFR over time (figure 4-7). These observations contradict Pennock and Wang (2008), 
proposing that c-Cbl is recruited earlier than Cbl-b. The weaker signal of c-Cbl compared to 
Cbl-b on endosomes during live imaging reduced confidence in the analysis and in order to 
get conclusive results, these experiments need therefore to be repeated. Independent of the 
tag, however, there appeared to be a weaker signal of c-Cbl than Cbl-b on endosomes after 
EGF addition (data not shown). IP of GFP-tagged c-Cbl and Cbl-b verified  that significantly 
more EGFR was precipitated with Cbl-b than c-Cbl, indicating that Cbl-b binds a larger 
proportion of EGFR than c-Cbl.  
 
The observed more efficient interaction between Cbl-b and the EGFR, compared to c-Cbl, 
has not been demonstrated before. An increased interaction between receptor and Cbl can be 
due to increased number of Cbl proteins binding to EGFR, which would give the increased 
signal as observed by live imaging. However, as more Cbl-proteins bind to one EGFR-
molecule, the fraction of EGFR precipitated with Cbl would be reduced. Increased interaction 
of EGFR with Cbl could alternatively be explained by the same amount of Cbl-binding for 
the two isoforms, but one binding with higher affinity to the EGFR. Precipitation of Cbl 
might then give an increased fraction of precipitated EGFR, but this would not give any 
difference in signal intensities for the two isoforms by live imaging. Therefore, these two 
explanations for increased interaction do not correlate with the findings in this thesis. 
However, if more EGFR molecules at the PM binds Cbl-b than c-Cbl, meaning not more Cbl 
molecules per EGFR molecules but a larger portion of EGFR binding Cbl-b than c-Cbl, a 
larger fraction of EGFR would precipitate with Cbl-b and a stronger signal from Cbl-b would 
be observed by live imaging. The latter explanation is in accordance with the findings in this 
thesis. We therefore believe that a larger fraction of EGFR binds Cbl-b than c-Cbl upon 
EGFR activation. The different efficiencies in recruitment of c-Cbl and Cbl-b to the EGFR 
might be explained by the ability of Cbl-b to bind ubiquitinated proteins through its UBA 
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domain (Davies et al., 2004) and thus display higher affinity for the ubiquitinated EGFR. The 
previous demonstrations from Pennock and Wang (2008) that Cbl-b may have additional 
binding sites than c-Cbl on the EGFR, might also be a probable explanation for the apparent 
differences in recruitment of c-Cbl and Cbl-b to EGFR.  
 
Our findings that there was a more efficient interaction between Cbl-b and EGFR compared 
to c-Cbl and the fact that Cbl has been demonstrated to increase the EGF-induced 
phosphorylation of the endosomal ubiquitin-sorting protein Hrs (Stern et al., 2007), prompted 
us to investigate whether transport of the EGF receptor to Hrs positive endosomes could be 
different in c-Cbl contra Cbl-b overexpressing cells. Phosphorylation of Hrs is important for 
correct EGFR degradation (Haugen et al., 2013) and alterations in the trafficking pattern 
might thus affect the rate of EGF receptor downregulation and degradation. As Cbl increases 
the EGF-induced phosphorylation of Hrs (Stern et al., 2007), a difference in the trafficking of 
c-Cbl and Cbl-b might influence the phosphorylation of Hrs. The notion that both Cbl and 
Hrs are associated with the adaptor protein CIN85 (Ronning et al., 2011; Soubeyran et al., 
2002), might open the possibility that Cbl somehow regulate phosphorylation of Hrs through  
CIN85.  
 
We investigated the intracellular trafficking of c-Cbl and Cbl-b to early endosomes, by 
transiently cotransfecting HeLa and HeLa Ii cells with either EGFP-c-Cbl or EGFP-Cbl-b 
together with RFP-Hrs, where Hrs was used as a marker for early endosomes (figure 4-8 and 
4-9). Quantifications of Hrs-transfected cells (figure 4-9 and 4-11 A and B) showed the same 
pattern in the colocalization of c-Cbl and Cbl-b with EGF compared to in cells cotransfected 
with c-Cbl and Cbl-b (figure 4-6). A weaker signal from c-Cbl than Cbl-b was observed in 
both Hrs-transfected cells upon stimulation with EGF, as observed in cells cotransfected with 
c-Cbl and Cbl-b. The somewhat different curves of the colocalization of c-Cbl and EGF in 
Hrs transfected cells compared to cells cotransfected with c-Cbl and Cbl-b, could be 
explained by the weaker c-Cbl signal in cells cotransfected with c-Cbl and Cbl-b. The 
colocalization pattern of both c-Cbl and Cbl-b with Hrs positive endosomes appeared to be 
quite similar (figure 4-9 and 4-11 C and D). Likewise, colocalization of Hrs and EGF started 
after 4 minutes in cells overexpressing either c-Cbl or Cbl-b (figure 4-9 and 4-11 E and F). 
Together, these analysis indicated that both c-Cbl and Cbl-b appear to follow the same 
trafficking pattern regarding recruitment to EGFR and the transport to Hrs positive 
endosomes.  
Discussion 
 
 50 
 
An interesting note is the analysis of the live imaging at longer time points. Analysis of the 
experiment with cells cotransfected with DsRed-c-Cbl and EGFP-Cbl-b (supplementary 
figure 2, movie S1) shows that both c-Cbl and Cbl-b have a peak of colocalization with EGF 
after 15 minutes, followed by a drop in colocalization when it comes to Cbl-b and EGF. 
Further, analysis of cells cotransfected with EGFP-c-Cbl and RFP-Hrs (supplementary figure 
3, movie S2) demonstrates that colocalization of c-Cbl and EGF had the same peak as 
colocalization with EGF and Hrs. While there is a decline in c-Cbl colocalizing with EGF 
and Hrs, there is a prolonged colocalization with EGF and Hrs. This might indicate a 
transport of EGFR into ILV in MVBs, which is as expected. A similar drop in c-Cbl and EGF 
colocalization could not be detected in cells cotransfected with c-Cbl and Cbl-b. However, in 
the movie of the cells co-transfected with c-Cbl and Cbl-b, the c-Cbl signal on endosomes is 
very weak and considering that these movies are based on one experiment each and with 
overexpression of different proteins, these experiments must be repeated in order to be able to 
detect any clear pattern. Nevertheless, the imaging experiments together with the results from 
the coprecipitations of Cbl and EGFR, contradicts Pennock and Wang (2008), stating that 
Cbl-b is recruited later than c-Cbl and shows somewhat prolonged association with EGFR 
after a decline in c-Cbl association. 
 
Taken together, the results in this thesis indicate that Cbl-b is more efficiently recruited to the 
EGF receptor. However, both c-Cbl and Cbl-b seem to follow the same trafficking pattern 
both regarding the recruitment to EGFR and the trafficking to early endosomes. 
 
 
 
 
Future perspectives 
 
51 
6 Future perspectives 
In this study, we have found that Cbl-b is more efficiently recruited to the EGFR than c-Cbl, 
but this does not appear to affect the intracellular trafficking of the EGFR at early time 
points. Therefore, further questions remain as to whether there are any differences in the 
activity of c-Cbl and Cbl-b at later time points. As knockout of one of them does not seem to 
affect EGFR trafficking (Pennock and Wang, 2008), it can be speculated if the more efficient 
recruitment of Cbl-b could affect the half-life of signaling proteins rather than affecting 
EGFR trafficking. The cause for the efficient recruitment of Cbl-b to EGFR needs to be 
clarified and it would be interesting to investigate its binding sites. A possible approach may 
be to mutate tyrosines in EGFR upstream of the deletion sites in the paper from Pennock and 
Wang (2008) and delete the UBA domain in Cbl-b. Lastly, we would like to investigate the 
late effects of c-Cbl contra Cbl-b overexpression on EGFR, by comparing EGFR degradation 
efficiency and by measuring growth and duration of signaling. 
 
Unfortunately, we were not able to get long timecourse movies of cells cotransfected with 
Cbl-b and Hrs as these cells were very sensitive to imaging. In cells cotransfected with c-Cbl 
and Cbl-b, and c-Cbl and Hrs, the patterns somewhat contradicted each other as c-Cbl 
seemed to disappear from endosomes after 11 minutes of EGF addition, while in c-Cbl and 
Cbl-b co-transfected cells c-Cbl still colocalized with EGF after 87 minutes. As the imaging 
results presented in this thesis are only based on one film in each experiment, more 
experiments for each condition using only one cell line is needed to make definite 
conclusions. Also, the cotransfection of Cbl-b and Hrs must be optimalized to get longer 
movies.  
 
Further, since both c-Cbl and Cbl-b appear to colocalize with Hrs positive endosomes at the 
same time, it would be of great advantage to be able to optimalize live imaging with Cbl on Ii 
induced Hrs positive enlarged endosomes to investigate if they might affect the localization 
of EGF and Cbl on distinct microdomains on the Hrs positive endosomes differently.Cbl has 
been shown to increase EGFR induced phosphorylation of Hrs and preliminary results 
showed that both Cbl-proteins induce increased Hrs phosphorylation upon EGFR activation. 
These experiments need to be optimalized, but it would be very interesting to investigate 
whether the more efficient Cbl-b recuitment affects Hrs function through phosphorylation, as 
this modification is important for correct EGFR trafficking.  
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Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S1. Count of pixels representing Alexa 647-EGF positive structures. 
Pixel count of Alexa 647-EGF structures in cells cotransfected with DsRed-c-Cbl and 
EGFP-Cbl-b (movie S1) (Red), EGFP-c-Cbl and RFP-Hrs (movie S2) (Green), and EGFP-
Cbl-b and RFP-Hrs (movie S3) (Blue). All images were analyzed in ImageJ.   
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Figure S2 
 
 
Figure S2. Quantification of colocalization of c-Cbl and EGF, and Cbl-b and EGF at longer time points. 
Quantification of live imaging in figure 4-5 (movie S1), analyzed in ImageJ. 
 A and C: Percentage of colocalized pixels measured as number of pixels showing colocalization of c-Cbl and 
EGF (A) or Cbl-b and EGF (C) out of total number of pixels in ROI. B and D: Percentage colocalization 
meaured as fraction of colocalized pixels relative to the total number of c-Cbl or EGF (B) pixels or number of 
Cbl-b or EGF (D) pixels in the ROI. The analysis was based on one experiment.  
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Figure S3 
 
Figure S3. Quantification of colocalization of c-Cbl and EGF, c-Cbl and Hrs and Hrs and EGF at longer 
time points.  
Quantification of live imaging in figure 4-8 (movie S2), analyzed in ImageJ. 
A: Percentage colocalization of c-Cbl and EGF in ROI. B: Percentage colocalization relative to the amount of c-
Cbl or EGF in the ROI. C: Percentage colocalization of c-Cbl and Hrs in ROI. D: Percentage colocalization 
relative to the amount of c-Cbl or Hrs in the ROI. E: Percentage colocalization of Hrs and EGF ROI. F: 
Percentage colocalization relative to the amount of Hrs or EGF in the ROI. 
 
 
. 
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Table S1: Antibodies 
 
* Harald Stenmark, Centre for Cancer Biomedicine, Norwegian Radium Hospital, University of Oslo, Oslo, 
Norway. 
 
 
 
 
 
 
 
 
 
Antibody Class Epitope Purchased 
from 
Concentration  for 
WB 
Concentration 
for IP 
Primary (P)/ 
Secondary (S) 
Anti c-Cbl Rabbit IgG c-Cbl (human) Santa Cruz, CA, 
USA 
1:500  P 
Anti Cbl-b  Rabbit IgG Cbl-b (human) Santa Cruz, CA, 
USA 
1:200  P 
Anti Hrs Rabbit IgG Hrs (mouse) Harald Stenmark* 1:1000  P 
Anti EGFR Sheep IgG EGFR (human) Fitzgerald, MA, 
USA 
1:10000  P 
M-B741 Mouse IgG Ii C-terminus (all 
isoforms) (human) 
Santa Cruz, CA, 
USA 
1:5000  P 
Anti tubulin Mouse ascites N-terminus of α-
tubulin (various 
species) 
Zymed 
Laboratories, CA, 
USA 
1:5000  P 
Anti GFP Rabbit  Abcam, 
Cambridge, UK  
1:1000 1µg P 
Sheep anti-mouse 
IgG HRP-linked 
Sheep IgG  GE Healthcare, 
Buckinghamshire, 
UK 
1:10000  S 
Donkey anti-rabbit 
IgG HRP-linked 
Donkey IgG  GE Healthcare, 
Buckinghamshire, 
UK 
1:10000  S 
Rabbit Anti-sheep Rabbit IgG  Southern Biotech, 
AL, USA 
1:8000  S 
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Table S2: Lysis buffers 
 
Lysis buffer for Western Blot 
Ingredients Concentration   
Tris-HCl (pH 6.8) 50 mM   
EDTA (pH 8) 5 mM   
NaF 30 mM   
Sodium pyrophosphate 50 mM   
dH2O  Adjustment to desired volume   
0,5 % Nonidet P-40 and 1:100 protease inhibitor (Roche, Basel Switzerland) was added 
before use 
 
 
Lysis buffer for immunoprecipitation 
Ingredients Concentration   
Sodium phosphate-buffer (pH 7,2)  0.01 mM   
EDTA (pH 8) 10 mM   
NaF 30 mM   
NaCl 0.15 mM   
dH2O  Adjustment to desired volume   
0,5 % Nonidet P-40, 1:100 protease inhibitor (Roche), 1:100 phosphatase inhibitor 
cocktail (Sigma-Aldrich) and 100 mM n-ethylmaleimide was added before use 
 
 
 
Table S3: Hepes Running buffer (1x) 
Ingredients Concentration 
Tris 10 mM 
Hepes 35 mM 
SDS 3 mM 
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dH2O  Adjustment to desired volume 
 
 
Table S4: Transfer buffer (1x) 
Ingredients Concentration   
Glycine 380 mM   
Tris 50 mM   
Methanol (Sigma-Aldrich) 10 %   
dH2O  Adjustment to desired volume   
 
 
Table S5: TBS (1x) (pH 7.6) 
Ingredients Concentration 
Tris 20 mM 
NaCl 0,0137 mM 
dH2O  Adjustment to desired volume 
 
 
Table S6: Gel loading buffer (6 x) for Western blot 
Ingredients Concentration 
Glycerol 30 % 
Bromophenol blue 0,3 % 
-mercaptoethanol 24 % 
SDS 12 % 
dH2O  Adjustment to desired volume 
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Table S7: Gel loading buffer (2 x) for 
immunoprecipitation 
 
Ingredients Concentration 
Glycerol 10 % 
Bromophenol blue 0,01 % 
-mercaptoethanol 8 % 
SDS 4 % 
EDTA (pH 8) 10 mM 
Na pyrophosphate 60 mM 
NaF 100 mM 
Tris-HCl (pH 6,8) 125 mM 
dH2O  Adjustment to desired volume 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary 
 
67 
 
Supplementary movies 
 
 
Movie S1: Trafficking of c-Cbl and Cbl-b 
HeLa cells were transiently cotransfected with DsRed-c-Cbl and EGFP-Cbl-b and stimulated 
with 100 ng/ml Alexa 647-tagged EGF under live imaging at 37 °C using Spinning Disc 
confocal microscopy. Note: The movie has a longer time scale than the movie with HeLa Ii 
cells cotransfected with EGFP-Cbl-b and RFP-Hrs. 
Scale bar = 10 μm 
 
Movie S2: Trafficking of c-Cbl and Hrs 
HeLa cells were transiently cotransfected with EGFP-c-Cbl and RFP-Hrs at 37 °C over night 
and stimulated with 100 ng/ml Alexa 647-tagged EGF under live imaging using Spinning 
Disc confocal microscopy. 
Note: The movie has a longer time scale than  the movie with HeLa Ii cells cotransfected 
with EGFP-Cbl-b and RFP-Hrs. 
Scale bar = 10 μm 
 
Movie S3: Trafficking of Cbl-b and Hrs 
HeLa Ii cells were transiently cotransfected with EGFP-Cbl-b and RFP-Hrs at 37 °C over 
night and stimulated with 100 ng/ml Alexa 647-tagged EGF under live imaging using 
Spinning Disc confocal microscopy. 
Scale bar = 10 μm 
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Appendix 
 
Previous master project 
 
Initially, the master project was to study the role of Hrs and Eps15 in intracellular trafficking 
of the FcεRI, the high affinity receptor for IgE. The study was thought to investigate if Hrs 
and Eps15 had similar functions in the intracellular trafficking of FcεRI as for the EGF 
receptor (Haugen et al., 2013). Mast cells (RBL-2H3) were used to study the degranulation 
response resulting from stimulation of FcεRI with IgE cross bound with allergen. Both 
degranulation assays, immunoprecipitations, Flow cytometry, live imaging and imaging of 
fixed cells were applied. Unfortunately, the cells were not responding properly giving 
contradicting results and there were difficulties finding appropriate antibodies against the 
subunits of FcεRI in the biochemical experiments. The project was ended september last year 
after a year with attempts to get trustworthy results.  
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